How many drugs treat Excessive salivation?

Drug Landscape tracks 4 marketed treatments for Excessive salivation (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/excessive-salivation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Excessive salivation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Excessive salivation (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Excessive salivation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cuvposa	GLYCOPYRRONIUM BROMIDE	Shionogi	Anticholinergic	Muscarinic acetylcholine receptor M1	1961-01-01
(-)-Atropine	Hyoscyamine	University of Kansas Medical Center	hyoscyamine	Muscarinic acetylcholine receptor M4
Glycopyrrolate	Glycopyrrolate	Yonsei University		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Sialanar	Sialanar	Proveca Pharma Limited		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Proveca Pharma Limited · 1 drug in Excessive salivation
Shionogi · 1 drug in Excessive salivation
University of Kansas Medical Center · 1 drug in Excessive salivation
Yonsei University · 1 drug in Excessive salivation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Excessive salivation:

Cite this brief

Drug Landscape (2026). Excessive salivation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/excessive-salivation. Accessed 2026-06-10.

Excessive salivation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing